Jefferies Group Analysts Raise Earnings Estimates for Spark Therapeutics, Inc. (ONCE)

Spark Therapeutics, Inc. (NASDAQ:ONCE) – Analysts at Jefferies Group boosted their FY2017 earnings per share (EPS) estimates for shares of Spark Therapeutics in a research note issued to investors on Monday. Jefferies Group analyst G. Wang now forecasts that the firm will post earnings per share of ($3.57) for the year, up from their previous forecast of ($4.23). Jefferies Group currently has a “Hold” rating and a $57.00 price target on the stock. Jefferies Group also issued estimates for Spark Therapeutics’ FY2018 earnings at ($2.41) EPS, FY2019 earnings at $0.40 EPS and FY2020 earnings at $5.18 EPS.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Thursday, November 3rd. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.01) by $0.06. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The business earned $1.30 million during the quarter, compared to analyst estimates of $1.26 million. During the same period in the previous year, the company earned ($0.70) earnings per share. The business’s revenue for the quarter was up .0% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark and copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2017/01/11/jefferies-group-analysts-raise-earnings-estimates-for-spark-therapeutics-inc-once.html.

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

A number of other equities research analysts also recently weighed in on the company. Wedbush reaffirmed an “underperform” rating and set a $28.00 price target on shares of Spark Therapeutics in a research note on Monday, December 5th. Zacks Investment Research downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 9th. Vetr downgraded Spark Therapeutics from a “buy” rating to a “hold” rating and set a $62.50 price target for the company. in a research note on Tuesday. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Spark Therapeutics in a research note on Monday, November 7th. Finally, Chardan Capital reaffirmed a “neutral” rating and set a $47.50 price target (down from $55.00) on shares of Spark Therapeutics in a research note on Monday, November 7th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $60.69.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down 7.65% during trading on Wednesday, hitting $57.35. The company’s stock had a trading volume of 377,439 shares. The firm’s 50 day moving average is $53.39 and its 200-day moving average is $55.20. Spark Therapeutics has a 1-year low of $21.20 and a 1-year high of $65.99. The company’s market capitalization is $1.76 billion.

A number of hedge funds have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. acquired a new stake in Spark Therapeutics during the third quarter worth about $28,290,000. Wells Fargo & Company MN raised its stake in Spark Therapeutics by 489.9% in the third quarter. Wells Fargo & Company MN now owns 134,331 shares of the company’s stock worth $8,068,000 after buying an additional 111,559 shares during the period. First Trust Advisors LP acquired a new stake in Spark Therapeutics during the third quarter worth about $1,688,000. Neuberger Berman Group LLC raised its stake in Spark Therapeutics by 38.9% in the third quarter. Neuberger Berman Group LLC now owns 12,500 shares of the company’s stock worth $751,000 after buying an additional 3,500 shares during the period. Finally, Swiss National Bank raised its stake in Spark Therapeutics by 23.2% in the second quarter. Swiss National Bank now owns 36,600 shares of the company’s stock worth $1,871,000 after buying an additional 6,900 shares during the period. 82.98% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark and copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2017/01/11/jefferies-group-analysts-raise-earnings-estimates-for-spark-therapeutics-inc-once.html.

In other Spark Therapeutics news, Director Anand Mehra sold 349,656 shares of the firm’s stock in a transaction that occurred on Friday, December 16th. The stock was sold at an average price of $53.46, for a total value of $18,692,609.76. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Barge Joseph La sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $52.98, for a total value of $158,940.00. Following the completion of the sale, the insider now directly owns 8,325 shares in the company, valued at approximately $441,058.50. The disclosure for this sale can be found here. 9.60% of the stock is owned by company insiders.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

5 Day Chart for NASDAQ:ONCE

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply